A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
KPV (lysine-proline-valine) is a tiny 3-amino-acid fragment of a larger hormone called alpha-MSH — a hormone your body already uses to regulate pigmentation, fever, and importantly, to dial down inflammation once an immune response has done its job. What makes KPV interesting is a discovery from 1989: researchers found that this small fragment alone retains the anti-inflammatory power of the full hormone, even though it’s too small to actually bind the receptors alpha-MSH normally uses.
That’s a meaningful distinction. Because KPV skips the melanocortin receptor pathway entirely, it doesn’t cause the tanning effect or appetite suppression that full alpha-MSH (or riskier compounds like Melanotan II) can cause — it appears to work by getting inside cells directly and blocking a key inflammatory signaling switch (NF-κB), reducing its activity by as much as 80% in lab models. Its small size also makes it unusually resistant to being broken down in the digestive tract, which is why you’ll see it studied in oral, injectable, and topical forms.
KPV has roughly two decades of laboratory and animal research behind it — including animal models of inflammatory bowel conditions (Crohn’s, ulcerative colitis), atopic and contact dermatitis, and mast cell activation — but as of 2026, there are no large completed human clinical trials in any of these areas. What exists in human use is built on a combination of that animal research and real-world practitioner experience, which is an honest gap worth naming even though the mechanistic research behind it is genuinely well-established.
Inflammatory signaling pathways are influenced by nutrient status broadly — omega-3 fatty acids, vitamin D, zinc, and magnesium are commonly discussed in the general nutrition literature on balanced inflammatory signaling, and are worth having in place alongside any protocol targeting this pathway.
KPV is not FDA-approved for any indication. On April 15, 2026, it was removed from the FDA’s 503A Category 2 list (a procedural step, not an approval), and it was one of four compounds reviewed by the Pharmacy Compounding Advisory Committee on July 23, 2026 (alongside BPC-157, TB-500, and MOTS-c), where FDA staff briefing materials proposed against inclusion on the list that would make compounding lawful. Its legal compounding status remains unresolved as of this writing. This page describes research findings only — it is not a claim about effects in humans and not an offer to treat any condition.
Laboratory research has examined KPV’s interaction with NF-κB, a transcription factor central to the body’s inflammatory gene expression. This is cell-culture and animal-model research; there are no completed controlled human clinical trials establishing an anti-inflammatory effect of KPV in people.
KPV corresponds to a fragment of alpha-MSH, a hormone with its own documented role in several regulatory pathways, which is why fragments of it have drawn separate research interest.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
